Carlyle and GTCR to buy AMRI for $21.75 per share
The Carlyle Group and GTCR have agreed to acquire Albany Molecular Research Inc, a global contract research, development and manufacturing organization working with the life sciences industry, for $21.75 per share. Credit Suisse Securities (USA) LLC is providing financial advice to AMRI on the transaction while Morgan Stanley & Co. LLC is doing likewise for Carlyle. And, RBC Capital Markets LLC is serving as financial adviser to GTCR on the deal.
6 June 2017•5 mins read
